8-K: DOJ Approves Amedisys-UnitedHealth Merger with Divestitures

Amedisys and UnitedHealth Group reached a proposed final judgment with the U.S. Department of Justice and several states, clearing a significant hurdle for their merger, pending judicial approval and required divestitures.

Summary

• The U.S. Department of Justice (DOJ) and Attorneys General of Maryland, Illinois, New Jersey, and New York filed a Proposed Final Judgment with the U.S. District Court for the District of Maryland on August 7, 2025.
• The Proposed Final Judgment was agreed to by Amedisys, Inc. and UnitedHealth Group Incorporated.
• If approved, this judgment resolves the DOJ's and States' opposition to the previously announced merger transaction between UnitedHealth Group and Amedisys, contemplated under the Merger Agreement dated June 26, 2023 (modified December 26, 2024).
• Approval requires the parties to carry out certain divestitures within 75 days of the Court's entry of an Asset Preservation/Hold Separate Stipulation and Order or within 60 days of receipt of all necessary merger clearances under Indiana and West Virginia law, whichever is later.
• The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act, 15 U.S.C. § 16, for the limited purpose of determining whether it is in the public interest.
• Completion of the Merger remains subject to other closing conditions specified in the Merger Agreement.

Sentiment

Score: 8

Explanation: The resolution of the DOJ's opposition is a major positive step towards completing a significant merger, removing a key uncertainty. While divestitures are required, they are a condition for approval, not a new negative surprise. The overall sentiment is highly positive regarding the merger's progression.

Positives

• Resolution of opposition from the U.S. Department of Justice and several State Attorneys General to the merger.
• Agreement on a Proposed Final Judgment moves the merger closer to completion.

Negatives

• Required divestitures as a condition for merger approval.

Risks

• Termination of the Merger Agreement or inability to complete the Merger on anticipated terms or by the end of the Waiver Period.
• Inability to complete the Merger due to failure to satisfy all closing conditions in a timely manner or at all.
• Risk that a regulatory approval required for the Merger is delayed, is not obtained, or is obtained subject to unanticipated conditions.
• Effect of the pendency of the Merger on Amedisys' ability to maintain relationships with its patients, payers, and providers and retain its management and key employees.
• Costs related to the Merger.
• Diversion of management's time and attention from ordinary course business operations to completion of the Merger and integration matters.
• Risk of litigation or regulatory action related to the Merger, including the lawsuit filed by the DOJ.
• Inability to complete contemplated divestitures due to failure to satisfy all closing conditions in a timely manner or at all.

Future Outlook

The merger's completion is contingent on judicial approval of the Proposed Final Judgment and the successful execution of required divestitures. Management anticipates benefits and synergies from the merger, but acknowledges inherent uncertainties and risks that could affect the timing and outcome.

Management Comments

• Amedisys undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
• You are cautioned not to rely on Amedisys forward-looking statements.

Industry Context

This development is significant for the healthcare industry, particularly the home health and hospice sectors, as it signals the potential consolidation of a major player (Amedisys) into one of the largest diversified healthcare companies (UnitedHealth Group). Such mergers can reshape market dynamics, influence competition, and potentially impact service delivery models and pricing across the sector. The DOJ's involvement highlights ongoing antitrust scrutiny in healthcare M&A.

Legal Proceedings

• The U.S. Department of Justice (DOJ) along with the Attorneys General of Maryland, Illinois, New Jersey, and New York filed a proposed final judgment with the U.S. District Court for the District of Maryland to resolve their opposition to the merger.
• The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act.

Stakeholder Impact

• Shareholders: Increased likelihood of merger completion, potentially leading to the realization of the merger consideration.
• Management & Employees: Potential for integration challenges and diversion of attention, but also potential for new opportunities within the combined entity. Retention of key employees is a stated risk.
• Patients, Payers, and Providers: Potential for changes in service offerings or relationships post-merger, though the filing doesn't detail specific impacts.

Next Steps

• Judicial approval of the Proposed Final Judgment under the Antitrust Procedures and Penalties Act.
• Completion of required divestitures within 75 days of Court's entry of an Asset Preservation/Hold Separate Stipulation and Order or 60 days of necessary merger clearances under Indiana and West Virginia law, whichever is later.
• Satisfaction of all remaining conditions to closing as specified in the Merger Agreement.

Key Dates

Recommendation

The filing indicates significant progress towards the completion of the merger with UnitedHealth Group, resolving a major regulatory hurdle. This reduces uncertainty and makes the merger more likely to close. For investors, the primary remaining action is the judicial approval and the completion of divestitures. Given the advanced stage and the resolution of the DOJ's opposition, holding the stock seems appropriate to realize the merger consideration, assuming the deal terms are favorable. There's limited upside beyond the merger price, but the downside risk from regulatory blockage has significantly decreased.

Keywords

Amedisys, UnitedHealth Group, Merger, Acquisition, DOJ, Antitrust, Divestitures, Healthcare, Home Health, Hospice, SEC Filing, 8-K